Literature DB >> 667830

Proliferation kinetics of a human breast cancer line in vitro following treatment with 17beta-estradiol and 1-beta-D-arabinofuranosylcytosine.

R R Weichselbaum, S Hellman, A J Piro, J J Nove, J B Little.   

Abstract

The effect of 17beta-estradiol on an estrogen receptor-positive human breast cancer cell line (MCF-7) was studied. Low concentrations (10(-9) M) of 17beta-estradiol enhanced the rate of cell proliferation; the overall cell cycle time was shortened; and the proportion of cells in the S phase increased. Higher concentrations (10(-7) M) suppressed proliferation and slightly decreased the proportion of the cells in DNA synthesis. When combined with 1-beta-D-arabinofuranosylcytosine, an S-phase-specific chemotherapeutic agent, 10(-9) M 17beta-estradiol enhanced cell killing. This enhancement was not observed with 10(-7) M 17beta-estradiol. Kinetic changes caused by hormones have profound implications in clinical therapy, since the efficacy of cycle active agents may be altered.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 667830

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  22 in total

1.  Multifactor dimensionality reduction analysis to elucidate the cross-talk between one-carbon and xenobiotic metabolic pathways in multi-disease models.

Authors:  Shaik Mohammad Naushad; Sana Venkata Vijayalakshmi; Yedluri Rupasree; Nadella Kumudini; Sampathkumar Sowganthika; Janardhanan Venketlakshmi Naidu; M Janaki Ramaiah; Dunna Nageswara Rao; Vijay Kumar Kutala
Journal:  Mol Biol Rep       Date:  2015-02-04       Impact factor: 2.316

2.  The management of nonmetastatic locally advanced breast cancer using primary induction chemotherapy with hormonal synchronization followed by radiation therapy with or without debulking surgery.

Authors:  R A Sorace; C S Bagley; A S Lichter; D N Danforth; M W Wesley; R C Young; M E Lippman
Journal:  World J Surg       Date:  1985-10       Impact factor: 3.352

3.  Estrogen is increased in male cholangiocarcinoma patients' serum and stimulates invasion in cholangiocarcinoma cell lines in vitro.

Authors:  Taweewun Hunsawong; Ekapot Singsuksawat; Nuannapa In-chon; Watinee Chawengrattanachot; Chanitra Thuwajit; Banchob Sripa; Anucha Paupairoj; Siri Chau-in; Peti Thuwajit
Journal:  J Cancer Res Clin Oncol       Date:  2012-04-03       Impact factor: 4.553

4.  Role of proliferation and apoptosis in net growth rates of human breast cancer cells (MCF-7) treated with oestradiol and/or tamoxifen.

Authors:  P E Budtz
Journal:  Cell Prolif       Date:  1999-10       Impact factor: 6.831

Review 5.  Efforts to combine endocrine and chemotherapy in the management of breast cancer: do two and two equal three?

Authors:  M E Lippman
Journal:  Breast Cancer Res Treat       Date:  1983       Impact factor: 4.872

6.  Influence of estradiol on the total uptake and incorporation of thymidine in human breast cancer (MCF-7) in long-term cell culture. Comparison of autoradiographic and biochemical methods.

Authors:  R Coosen; P W de Jong; F Schwarz
Journal:  Mol Cell Biochem       Date:  1982-02-19       Impact factor: 3.396

7.  A phase II trial of tamoxifen, premarin, methotrexate and 5-fluorouracil in metastatic breast cancer.

Authors:  J C Allegra; T M Woodcock; S P Richman; K I Bland; J L Wittliff
Journal:  Breast Cancer Res Treat       Date:  1982       Impact factor: 4.872

8.  Establishment and characterization of a new human cell line (EJ) derived from endometrial carcinoma.

Authors:  Keiichi Isaka; Hirotaka Nishi; Toshihide Nakada; Yumi Osakabe; Mitsuyasu Hokamura; Hiromi Serizawa; Yoshiro Ebihara; Masaomi Takayama
Journal:  Hum Cell       Date:  2002-12       Impact factor: 4.174

9.  Insulin effects on methotrexate polyglutamate synthesis and enzyme binding in cultured human breast cancer cells.

Authors:  R L Schilsky; F S Ordway
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

10.  Proliferative inhibition of human breast carcinoma cells by high concentration estradiol does not alter radiosensitivity.

Authors:  D E Wazer; M Joyce; G Solares; R Schmidt-Ullrich
Journal:  Breast Cancer Res Treat       Date:  1991-08       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.